Current anti-vascular endothelial growth factor dosing regimens: benefits and burden.

Abstract

TOPIC To examine the outcomes of clinical trials and case studies that investigated the different dosing regimens used for the 3 intravitreal anti-vascular endothelial growth factor (VEGF) inhibitors that are available currently. The Comparisons of Age-Related Macular Degeneration (AMD) Treatments Trial (CATT) data are discussed briefly here and are… (More)
DOI: 10.1016/j.ophtha.2013.01.057

Topics

2 Figures and Tables

Cite this paper

@article{Haller2013CurrentAE, title={Current anti-vascular endothelial growth factor dosing regimens: benefits and burden.}, author={Julia A. Haller}, journal={Ophthalmology}, year={2013}, volume={120 5 Suppl}, pages={S3-7} }